Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (11-20 of 319) with videos related to

Pageof 32
Sort By:
Drugs & Aging|February 13, 2003
Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith
Cancer|January 28, 2003
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinomaMatthew R Smith
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancerMatthew R Smith
Current Opinion in Endocrinology, Diabetes, and Obesity|October 18, 2007
Androgen deprivation therapy for prostate cancer: new concepts and concernsMatthew R Smith
The New England Journal of Medicine|June 15, 2022
Darolutamide in Metastatic Prostate Cancer. ReplyMatthew R Smith
Clinical Advances in Hematology & Oncology : H&O|October 12, 2021
How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancerMatthew R Smith
The Journal of Urology|November 13, 2004
Osteoporosis and obesity in men receiving hormone therapy for prostate cancerMatthew R Smith
Nature Clinical Practice. Urology|February 14, 2006
Therapy Insight: osteoporosis during hormone therapy for prostate cancerMatthew R Smith
Cancer Treatment Reviews|October 19, 2005
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidenceMatthew R Smith
Urologic Oncology|July 3, 2008
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyondMatthew R Smith
Pageof 32

Showing results (11-20 of 319) with videos related to

Sort By:
Pageof 32
Drugs & Aging|February 13, 2003
Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith
Cancer|January 28, 2003
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinomaMatthew R Smith
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancerMatthew R Smith
Current Opinion in Endocrinology, Diabetes, and Obesity|October 18, 2007
Androgen deprivation therapy for prostate cancer: new concepts and concernsMatthew R Smith
The New England Journal of Medicine|June 15, 2022
Darolutamide in Metastatic Prostate Cancer. ReplyMatthew R Smith
Clinical Advances in Hematology & Oncology : H&O|October 12, 2021
How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancerMatthew R Smith
The Journal of Urology|November 13, 2004
Osteoporosis and obesity in men receiving hormone therapy for prostate cancerMatthew R Smith
Nature Clinical Practice. Urology|February 14, 2006
Therapy Insight: osteoporosis during hormone therapy for prostate cancerMatthew R Smith
Cancer Treatment Reviews|October 19, 2005
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidenceMatthew R Smith
Urologic Oncology|July 3, 2008
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyondMatthew R Smith
Pageof 32